Drug Profile


Alternative Names: Reximmune-C

Latest Information Update: 14 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Epeius Biotechnologies
  • Developer Epeius Biotechnologies Corporation
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 24 May 2010 Pharmacodynamics data from a phase I/II trial in Cancer released by Epeius Biotechnologies
  • 18 Mar 2010 Reximmune-C® is still under active development
  • 27 May 2008 Final efficacy and adverse events data from a phase I trial in Cancer released by Epeius Biotechnologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top